USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Mölnlycke Health Care AB

USPTO PatentsView assignee record - 124 granted patents across 39 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

RSS updates for this company

The verdict

According to USPTO PatentsView, Mölnlycke ranks #3,072 of 49,997 tracked US assignees by granted-patent volume, with 124 patents across 39 technology areas.

#3,072
of 49,997 US assignees by volume
Top 5%
by Innovation Score (57.4/100)
11.3
avg claims per patent
+84%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R3072 · Foreign Corporation #3,072 · 124 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MID 124 grants
  • TOP-DECILE #3,072/49,997
  • PHOTO-FINISH GC
  • CPC-FOCUS A61F · 39 areas
  • INNOV-PAR 57.4/100
  • CLAIMS-PAR 11.3 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-SURGE +84% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: GC Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Mölnlycke

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Mölnlycke's Innovation Score is 57.4/100 (top 5% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Mölnlycke's grants concentrate

Mölnlycke Health Care AB is a focused PatentsView assignee: 39 CPC subclasses with 40.3% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2023 (20 grants) versus a trough of 4 in 2018. By volume, Mölnlycke sits between GC Corporation and ENDRESS+HAUSER GMBH+CO.KG.

Mölnlycke's three-year grant acceleration

From 2019–2021 to 2022–2024, Mölnlycke Health Care AB moved from 27 to 48 grants (1.78x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #281. See the growth leaderboard.

Who files at Mölnlycke's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Mölnlycke holds 124 patents at rank #3,072, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Mölnlycke

By rank, the assignees closest to #3,072 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Mölnlycke's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Mölnlycke, neither rank-band nor same-CPC leaders (those blocks stay above).

Mölnlycke's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

57 Top 5% higher than 95% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0510152025 20152016201720182019202020212022202320242025 16
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Mölnlycke Health Care AB patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 9 7.3%
2016 11 8.9%
2017 9 7.3%
2018 4 3.2%
2019 5 4.0%
2020 11 8.9%
2021 11 8.9%
2022 10 8.1%
2023 20 16.1%
2024 18 14.5%
2025partial year 16 12.9%

Which technologies does Mölnlycke Health Care AB patent most?

Top 15 of 39 technology areas

Where it ranks

Overall rank by patents

#3,072

of 49,997 tracked assignees

Innovation Score

57.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Mölnlycke Health Care AB's patent record in context - here's where to go next.

  • Mölnlycke Health Care AB's lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 40.3% of its portfolio - see every assignee active in that class. Explore A61F
  • Ranked #3,072 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Mölnlycke Health Care AB against GC Corporation, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 57.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.